| Erin Bingham, APRN | |
|
62 Tilley Dr, South Burlington, VT 05403 | |
| (802) 847-3737 | |
| Not Available |
| Full Name | Erin Bingham |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 62 Tilley Dr, South Burlington, Vermont |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447745765 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | 026.0133177 (Vermont) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | 101.0134189 (Vermont) | Primary |
| Entity Name | University Of Vermont Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659309615 PECOS PAC ID: 3779491071 Enrollment ID: O20040406001047 |
News Archive
Despite many successes, modern medicine is still struggling to find effective treatments for serious pathologies such as cancer and neurodegenerative and inflammatory diseases. For Alzheimer's disease, for example, only 30% of patients respond to therapy whereas for cancers the figure is only 25%.
Four weeks of treatment with a novel inhaled medication failed to improve exercise capacity, daily activity levels, severity of symptoms or quality of life in patients with a type of heart failure for which no effective treatment options currently exist, according to research presented at the American College of Cardiology's 67th Annual Scientific Session.
As medical personnel and public health officials are responding to the first reported cases of Ebola Virus in the United States, many of the safety and treatment procedures for treating the virus and preventing its spread are being reexamined. One of the tenets for minimizing the risk of spreading the disease has been a 21-day quarantine period for individuals who might have been exposed to the virus. But a new study by Charles Haas, PhD, a professor in Drexel's College of Engineering, suggests that 21 days might not be enough to completely prevent spread of the virus.
Octapharma AG, one of the largest human protein products manufacturers in the world, and Octapharma USA today announced that patients diagnosed with severe hemophilia A have started treatment in a multi-center study that is researching the use of the first recombinant Factor VIII (rFVIII) derived from a human cell line (Human-cl rhFVIII).
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Erin Bingham, APRN 150 Allen Rd Unit 118, South Burlington, VT 05403-3802 Ph: () - | Erin Bingham, APRN 62 Tilley Dr, South Burlington, VT 05403 Ph: (802) 847-3737 |
News Archive
Despite many successes, modern medicine is still struggling to find effective treatments for serious pathologies such as cancer and neurodegenerative and inflammatory diseases. For Alzheimer's disease, for example, only 30% of patients respond to therapy whereas for cancers the figure is only 25%.
Four weeks of treatment with a novel inhaled medication failed to improve exercise capacity, daily activity levels, severity of symptoms or quality of life in patients with a type of heart failure for which no effective treatment options currently exist, according to research presented at the American College of Cardiology's 67th Annual Scientific Session.
As medical personnel and public health officials are responding to the first reported cases of Ebola Virus in the United States, many of the safety and treatment procedures for treating the virus and preventing its spread are being reexamined. One of the tenets for minimizing the risk of spreading the disease has been a 21-day quarantine period for individuals who might have been exposed to the virus. But a new study by Charles Haas, PhD, a professor in Drexel's College of Engineering, suggests that 21 days might not be enough to completely prevent spread of the virus.
Octapharma AG, one of the largest human protein products manufacturers in the world, and Octapharma USA today announced that patients diagnosed with severe hemophilia A have started treatment in a multi-center study that is researching the use of the first recombinant Factor VIII (rFVIII) derived from a human cell line (Human-cl rhFVIII).
› Verified 7 days ago
Leah M Flore, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 51 Timber Ln, South Burlington, VT 05403 Phone: 802-864-0521 Fax: 802-864-6475 | |
Elissa Ann Delong, WHNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 185 Tilley Dr, South Burlington, VT 05403 Phone: 802-862-7338 | |
Megan Houston, A.P.R.N. Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 50 Timber Ln, South Burlington, VT 05403 Phone: 802-862-6312 | |
Tracey Campbell, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 3 Timber Ln, South Burlington, VT 05403 Phone: 802-847-8500 | |
Leah Mariette Macaulay, P.N.P Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 51 Timber Ln, South Burlington, VT 05403 Phone: 802-864-0521 Fax: 802-864-6475 | |
Laurie M Davignon, CPNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 62 Tilley Dr Ste 202, South Burlington, VT 05403 Phone: 802-847-4576 | |
Peyton Wingfield, APRN FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 53 Timber Ln, South Burlington, VT 05403 Phone: 802-864-0294 |